Skip to main content

Day: December 27, 2019

Microbot Medical Inc. Announces Closing of $9.59 Million Registered Direct Offering of Common Stock

HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase price of $10.50 per share for total gross proceeds of approximately $9.59 million, before deducting placement agent fees and offering expenses.Microbot currently intends to use the net proceeds from this offering for the continuous development and regulatory activities for its SCS device for the treatment of hydrocephalus and NPH; continue the development of the Company’s LIBERTY robotic system, including its expansion through addition of complementary assets to it either through internal development, in-license or acquisitions; expand and develop additional applications deriving from its existing IP portfolio, either through internal...

Continue reading

Niko Provides Update on Settlement of Arbitration Case related to Interest in D6 Block in India

CALGARY, Alberta, Dec. 27, 2019 (GLOBE NEWSWIRE) — Niko Resources Ltd. (“Niko” or the “Company”) announces that an amendment to the production sharing contract for the D6 Block (“D6 PSC”) in India has been executed, reflecting the assignment of the 10 percent interest previously held by the Company’s indirect subsidiary, Niko (NECO) Ltd. (“Niko NECO”), to the remaining interest holders in the block, Reliance Industries Limited  (“Reliance”) and BP Exploration (Alpha) Limited (“BPEAL”). Niko NECO had entered into a settlement agreement with Reliance and BPEAL under which it agreed to withdraw  from D6 PSC and settle its arbitration case filed under the rules of the London Court of International Arbitration in December 2017 in exchange for...

Continue reading

electroCore Announces Board of Directors Transition

BASKING RIDGE, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox, will resign from the Board effective March 31, 2020. Ms. Cox also served on electroCore’s Audit and Nominating and Governance Committees. Michael Atieh, who joined the company’s Board in June 2018, will assume the role of Chairman.“I joined the electroCore Board because I firmly believe in the promise of the company’s vagus nerve stimulation technology to treat a broad range of medical indications non-invasively, and improve the lives of countless numbers of patients,” said Ms. Cox. “I am proud of the progress that we have made thus far, and I leave the Board believing...

Continue reading

Anything Technologies Media, Inc. Acquires Sonoran Flower LLC, an Arizona Licensed Hemp Company

LAS VEGAS, NV, Dec. 27, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Anything Technologies Media, Inc. (OTC: EXMT) is pleased to announce that the company has acquired Arizona based Sonoran Flower LLC. https://sonoranflower.com/About Sonoran Flower LLCSonoran Flower was built on the belief that nature holds everything we need to heal. We are a multifaceted organization that cultivates, processes, and sells wholesale and retail hemp goods. We procure and produce top-quality hemp seeds, smokable hemp flower, hemp biomass, distillates, isolates and products such as vape, lotions, and salves.To Purchase Sonoran Flower products please order @ https://sonoranflower.com/storePlease follow Sonoran Flower on Instagram @ https://www.instagram.com/azgrowbros/We are so excited about this partnership with Sonoran Flower, Stated Rick Wilson,...

Continue reading

INVL TECHNOLOGY HAS COMPLETED THE FORMATION OF AN IT SERVICES AND SOFTWARE BUSINESS GROUP

The special closed-ended private equity investment company INVL Technology has completed the formation of the Novian group of businesses with an IT-services-and-software focus. This process was completed in late December this year when, after the performance of internal business acquisitions, the amended articles of association of Novian UAB and BAIP UAB were registered at Lithuania’s Centre of Registers.“Following the reorganisation, the Novian group’s companies will expand the range of services they provide and will be able to meet clients’ needs to implement complex projects, since clients will be able to get more services from a single source,” said Kazimieras Tonkūnas, INVL Technology’s managing partner.In forming the Novian group, internal acquisitions were made: Novian UAB acquired Algoritmu...

Continue reading

„INVL TECHNOLOGY“ BAIGĖ FORMUOTI IT PASLAUGŲ IR PROGRAMAVIMO ĮMONIŲ GRUPĘ

Specialaus uždarojo tipo privataus kapitalo investicinė bendrovė „INVL Technology“ baigė formuoti IT paslaugų ir programavimo krypties įmonių grupę „Novian“. Šis procesas pabaigtas šių metų gruodžio pabaigoje, kai, atlikus vidinius įmonių įsigijimus, Registrų centre buvo įregistruoti pakeisti UAB „Novian“ ir UAB BAIP įstatai.„Po pertvarkos „Novian“ grupės bendrovės išplės teikiamų paslaugų spektrą bei galės patenkinti klientų poreikį įgyvendinti kompleksinius projektus, kadangi jie galės gauti daugiau paslaugų iš vienų rankų“, – sakė „INVL Technology“ vadovaujantysis partneris...

Continue reading

Regulus Announces Closing of C$11.5 Million Financing

Not for distribution to U.S. news wire services or dissemination in the United States.VANCOUVER, B.C., Dec. 27, 2019 (GLOBE NEWSWIRE) — Regulus Resources Inc. (“Regulus” or the “Company“) is pleased to announce that it has closed its previously announced bought deal financing, including the exercise in full of the underwriter’s option. A total of 7,783,875 units of the Company, each comprising one common share and one half of one common share purchase warrant (“Units“) were sold at a price of C$1.06 per Unit (the “Offering Price“), for aggregate gross proceeds of approximately $8.25 million (the “Public Offering“).Pursuant to a concurrent non-brokered private placement, 3,066,375 Units were sold to certain funds managed by Route One Investment Co. LP, the Company’s...

Continue reading

Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has entered into a Restructuring Support Agreement (the “Agreement”) with the lenders under its senior credit facility, Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. (the “Supporting Lenders”). Under the Agreement, the Supporting Lenders would acquire the Company as a going concern by exchanging $140 million of secured claims arising under its senior credit facility for 100 percent of the equity to be issued by the reorganized Company pursuant to a pre-negotiated chapter...

Continue reading

Mateon Therapeutics Team Publishes a New Peer-Reviewed Oncology Article on the Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients With Relapsed Acute Myeloid Leukemia

AGOURA HILLS, Calif., Dec. 27, 2019 (GLOBE NEWSWIRE) — Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD. PhD, the Chief Medical Officer for Mateon, Vuong Trieu, PhD, the Chief Executive Officer and President for Mateon and four hematology/oncology professors from academic US institutions in the prestigious oncology journal Cancers (Basel).The article describes in detail the data obtained in the recently completed multi-institutional OXI1222 study that was aimed to evaluate the clinical potential of Mateon’s lead anti-leukemia drug Combretastatin A1 (also known as OXi4503) in adult patients with previously treated relapsed acute myeloid leukemia (AML). This clinical study was registered at www.clinicaltrials.gov as NCT02576301. Patients were...

Continue reading

Tulare Project Begins Commercial Operation; Supports Achievement of Key Sustainability Goals

FuelCell Energy Power Plant Drives a Cleaner Energy Profile for San Joaquin Valley, Globally One of the Most Productive Agricultural Regions100% Renewable power contributes to California’s decarbonization objectivesProprietary FuelCell Technology Drives Reduction in particulates, NOx and SOx for Cleaner Air for all Californians20 Year Power Purchase Agreement To Supply California Electric Grid with baseload renewable energyDANBURY, Conn., Dec. 27, 2019 (GLOBE NEWSWIRE) — FuelCell Energy, Inc.  (Nasdaq: FCEL), a global leader in delivering clean, innovative and affordable fuel cell solutions for the supply, recovery and storage of energy, today announced the start of commercial operation of the 2.8 megawatt fuel cell project located at the city of Tulare, California’s waste water treatment facility, expanding the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.